Pharmacy and Therapeutics Committee Approvals, December 2007

P&T Date: December 11, 2007

Agenda Item	P&T Committee Decision	Comments
• **Ropivacaine (Naropin®)**	**Added to Formulary for Obstetrical Anesthesia ONLY.**	• ***Indications:*** (1) surgical anesthesia (epidural block, including cesarean section, major nerve block), (2) local infiltration and (3) acute pain management (epidural continuous infusion or intermittent bolus e.g. postoperative or labor) • ***Mechanism of Action:*** Blockade of nerve impulse generation and conduction by slowing propagation of nerve impulses and reduction or rate of rise of the action potential • ***Adverse effects:*** Most related to high plasma levels (related to overdosage, unintentional intravascular injection or decreased medication metabolism): hypotension, bradycardia, parasthesia, headache, nausea, vomiting • ***Precautions:*** Contraindicated in patients with known amide-type anesthetic allergies; consider dosage reduction in liver disease; potential cytochrome P-450_{1A2}-related drug-drug interactions
• **Lidocaine/Tetracaine Topical (Synera®)**	**Not added to Formulary.**	• ***Indications:*** Local dermal analgesia for superficial venous access and superficial dermatological procedures such as excision, electrodessication and shave biopsy of skin lesions • ***Mechanism of Action:*** Blockade of sodium ion channels required for the initiation and conduction of impulses, resulting in local anesthesia • ***Adverse effects:*** Most commonly: localized reactions (erythema, blanching and edema) • ***Precautions:*** Contraindicated with known hypersensitivity to lidocaine, tetracaine, local amide or ester-type anesthetics, or PABA. Potential synergistic effects with Class I antiarrhythmics or local anesthetic agents. Only apply to intact skin. Removal of top cover of patch can result in thermal injury. Patch should be removed prior to MRI.
• **Naltrexone Long-Acting Injection (Vivitrol®)**	**Not added to Formulary; approve on a case-by-case basis in the outpatient treatment clinic following prior insurance authorization ONLY**	• ***Indications:*** Treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of Vivitrol® treatment • ***Mechanism of Action:*** Opioid antagonist with highest affinity for mμ opioid receptor, which may be involved in alcohol consumption. Does not eliminate or attenuate symptoms of alcohol withdrawal • ***Adverse effects:*** Potential hepatocellular toxicity when given in excessive doses. Contraindicated with acute hepatitis or liver failure; carefully consider use in patients with active liver disease. Depression and suicidality more common in treated patients. One case report of eosinophilic pneumonia. May precipitate withdrawal syndrome in patients physically dependent on opioids. • ***Precautions:*** Contraindicated in patients receiving opioid analgesics, with current physiological opioid dependence or those with positive opioid urine screen. Pregnancy category C. Naltrexone-induced opioid blockade can be overcome with large doses of opioids, therefore opioid overdose is possible. Patients previously treated with Vivitrol® may require lower doses of opioids than previously used

• **INTERVENTIONAL NEURORADIOLOGY PHYSICIAN GUIDELINES FOR ABCIXIMAB (REOPRO®), TPA (ALTEPLASE) AND NICARDIPINE (CARDENE®)**	**GUIDELINES APPROVED; ALLOW NICARDIPINE INTRA-ARTERIAL USE AS PER "RESCUE TREATMENT OF VASOSPASM DURING INTERVENTIONAL NEURORADIOLOGY PROCEDURES" GUIDELINE ONLY**	Abciximab for Rescue in Neuroradio tPA Neuro IR Nicardipine Neuro IR
• **APROTININ (TRASYLOL®)**	**REMOVED FROM CSMC FORMULARY; US MARKETING HALTED BY BAYER**	B4b3. Aprotinin - FDA 10.07.pdf B4b3. Aprotinin - FDA 11.07.pdf

• **AUTOMATIC SUBSTITUTION**	• **Heparin 25,000 units/NS 250 ml <u>TO</u> Heparin 25,000 units/ ½ NS 250 ml (pre-made bag)**
• **CODE WHITE PROTOCOL REVISION**	Code White - revision
• **MEDICATION SAFETY ISSUES**	• **Mycophenolic acid delayed-release tab (Myfortic®) – Pregnancy category change to D** • **Rosiglitazone (Avandia®) FDA Black Box Warning and ADA Caution:** B4b4. Avandia Black Box Warning 11.07.p Avandia ADA 11 07 • **Epoetin (Epogen®) Revised FDA Warnings:** B4b5. Epoetin FDA Updated Warnings 11 • **Microbubble Contrast Agents (Definity®, Optison®) Alert – Use suspended at CSMC:** B4b6. Micro-bubble Contrast 10.07.pdf
• **HEPARIN PER PHARMACY PROTOCOL REVISION**	**Pharmacist will contact MD if <u>≥</u> 2 consecutive aPTTs are above desired range or <u>≥</u> 3 consecutive aPTTs are below desired range**

Requests for full monographs or questions regarding this listing may be addressed to the Drug Information Center at **(310) 423-3784**

Angela Hirai Yang, PharmD — *Pharmacy Program Coordinator*
Hai Tran, PharmD — *Clinical Coordinator*
Rita Shane, PharmD, FASHP — *Director, Department of Pharmacy*